Hospital Ruber Internacional
Medication treatment for multiple sclerosis in Spain typically costs from $3,000 to $6,000 depending on the specific drug protocol, clinic tier, and required diagnostic monitoring. In the US, similar treatments cost around $18,500 on average. Patients seeking care in Spain can achieve savings of approximately 76%. Budget estimates usually cover neurologist consultations, initial blood work, and the primary pharmacological therapy.
Bookimed Expert Insight: Spain offers elite neurological care with research-driven value. Quironsalud Madrid provides access to over 100 clinical trials for neurodegenerative disorders. For those seeking advanced diagnostics, Hospital HM Nou Delfos utilizes EOS imaging and MRI technology. Expert neurologists like Dr. Rafael Arroyo González, a published researcher in The Lancet, lead these programs. This allows patients to access world-class expertise at significantly lower private rates than North American alternatives.
Why do patients choose Spain for medication treatment for multiple sclerosis?
Access advanced Medication treatment for multiple sclerosis solutions in trusted clinics .
| Turkey | Austria | Spain | |
| Medication treatment for multiple sclerosis | from $2,500 | from $2,000 | from $3,000 |
| Ocrevus (ocrelizumab) | from $10,000 | from $35,000 | from $25,000 |
Day 1
Day 2
Day 3
Day 4 to Day 14
Week 3
Week 4
Week 5
Note: Each patient"s journey with multiple sclerosis differs. This plan is a general guideline and may be adjusted based on individual needs.
Principal investigator in 100+ clinical trials for multiple sclerosis – Dr. Arroyo leads groundbreaking research at Quironsalud Madrid.
Dr Romero Imbroda is a Fellow of the European Board of Neurology and President of the Andalusian Society of Neurology, specializing in multiple sclerosis treatment.
Dr. Rodrigo Rocamora Zuniga is a neurologist who specializes in epilepsy. He leads the epilepsy department at HM Delfos Hospital in Spain. He is also a professor at UPF University. Dr. Rocamora earned his PhD from Bonn University in 2001. He completed his neurology training at Pontificia Universidad Católica de Chile and received his medical degree in Mendoza, Argentina.
Dr. Rocamora is accredited by the European Reference Network. He is an active member of SEN, CSUR, and EPI-Care. He has published over 100 scientific articles on drug-resistant epilepsy, epilepsy surgery, and cognitive impairment. His work has helped develop new protocols that have improved care for epilepsy patients.